Advertisement

Journal of Gastroenterology

, Volume 47, Issue 11, pp 1177–1185 | Cite as

Altered neuro-endocrine–immune pathways in the irritable bowel syndrome: the top-down and the bottom-up model

  • Cristina Stasi
  • Massimo Rosselli
  • Massimo Bellini
  • Giacomo Laffi
  • Stefano Milani
Review

Abstract

The interaction between the brain and the gut as a pathological mechanism of functional gastrointestinal disorders has been recently recognized in the pathophysiology of the irritable bowel syndrome. Communication between central nervous system and enteric nervous system is two-directional: the brain can influence the function of the enteric nervous system and the gut can influence the brain via vagal and sympathetic afferents. In patients with irritable bowel syndrome, symptoms may be caused by alterations either primarily in the central nervous system (top-down model), or in the gut (bottom-up model), or in a combination of both. The brain–gut axis may be stimulated by various stressors either directed to the central nervous system (exteroreceptive stress) or to the gut (interoceptive stress). Particularly, clinical evidence suggest that in complex and multifactorial diseases such as irritable bowel syndrome, psychological disorders represent significant factors in the pathogenesis and course of the syndrome. Neuroimaging techniques have shown functional differences between central process in healthy subjects and patients with irritable bowel syndrome. Moreover, a high prevalence of psychological/psychiatric disorders have been reported in IBS patients compared to controls. Several data also suggest an alteration of neuro-endocrine and autonomic output to the periphery in these patients. This review will examine and discuss the complex interplay of neuro-endocrine–immune pathways, closely associated with neuropsychiatric disorders.

Keywords

Stress Corticotropin releasing hormone Mast cells Exteroreceptive stress Interoceptive stress 

Abbreviations

HPA

Hypothalamic–pituitary–adrenal axis

HANS

Hypothalamic–autonomic nervous system axis

IBS

Irritable bowel syndrome

PVN

Paraventricular nucleus

ACC

Anterior cingulated cortex

CNS

Central nervous system

PTSD

Post-traumatic stress disorder

EMS

Emotional motor system

GC

Glucocorticoid

CRH

Corticotropin-releasing hormone

NY

Neuropeptide Y

ACTH

Adrenocorticotropic hormone

MR

Mineralocorticoid receptor

GR

Glucocorticoid receptor

D-IBS

Diarrhea-predominant IBS

EC

Enterochromaffin cell

C-IBS

Constipation-predominant IBS

Notes

Acknowledgments

The authors thank Mrs. Susan Seeley for her help in editing the manuscript.

Conflict of interest

The authors have no conflicts of interest to disclose.

References

  1. 1.
    Mayer EA. The neurobiology of stress and gastrointestinal disease. Gut. 2000;47:861–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Straub RH, Herfarth H, Falk W, Andus T, Schölmerich J. Uncoupling of the sympathetic nervous system and the hypothalamic–pituitary–adrenal axis in inflammatory bowel disease? J Neuroimmunol. 2002;126:116–25.PubMedCrossRefGoogle Scholar
  3. 3.
    Stasi C, Orlandelli E. Role of the brain–gut axis in the pathophysiology of Crohn’s disease. Dig Dis. 2008;26:156–66.PubMedCrossRefGoogle Scholar
  4. 4.
    Drossman DA. The functional gastrointestinal disorders and the Rome II process. Gut. 1999;45:1–5.CrossRefGoogle Scholar
  5. 5.
    Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology. 2006;130:1377–90.PubMedCrossRefGoogle Scholar
  6. 6.
    Lovallo WR, Thomas TL. Stress hormones in psychophysiological research: emotional, behavioral, and cognitive implications. In: Cacioppo JT, Tassinary LG, Berntson GG, editors. Handbook of psychophysiology. Cambridge: Cambridge University Press; 2000. p. 342–67.Google Scholar
  7. 7.
    Lea R, Whorwell PJ. New insights into the psychosocial aspects of irritable bowel syndrome. Curr Gastroenterol Rep. 2003;5:343–50.PubMedCrossRefGoogle Scholar
  8. 8.
    Lydiard RB, Fossey MD, Marsh W, Ballenger JC. Prevalence of psychiatric disorders in patients with irritable bowel syndrome. Psychosomatics. 1993;34:229–34.PubMedCrossRefGoogle Scholar
  9. 9.
    Thijssen AY, Jonkers DM, Leue C, van der Veek PP, Vidakovic-Vukic M, van Rood YR, et al. Dysfunctional cognitions, anxiety and depression in irritable bowel syndrome. J Clin Gastroenterol. 2010;44:e236–41.PubMedCrossRefGoogle Scholar
  10. 10.
    Delvaux M, Denis P, Allemand H. Sexual abuse is more frequently reported by IBS patients than by patients with organic digestive diseases or controls. Results of a multicentre inquiry. French Club of Digestive Motility. Eur J Gastroenterol Hepatol. 1997;9:345–52.PubMedCrossRefGoogle Scholar
  11. 11.
    Bennett EJ, Tennant CC, Piesse C, Badcock CA, Kellow JE. Level of chronic life stress predicts clinical outcome in irritable bowel syndrome. Gut. 1998;43:256–61.PubMedCrossRefGoogle Scholar
  12. 12.
    O’Mahony SM, Hyland NP, Dinan TG, Cryan JF. Maternal separation as a model of brain–gut axis dysfunction. Psychopharmacology (Berl). 2011;214:71–88.CrossRefGoogle Scholar
  13. 13.
    Irwin C, Falsetti SA, Lydiard RB, Ballenger JC, Brock CD, Brener W. Comorbidity of posttraumatic stress disorder and irritable bowel syndrome. J Clin Psychiatry. 1996;57:576–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Prior A, Colgan SM, Whorwell PJ. Changes in rectal sensitivity after hypnotherapy with irritable bowel syndrome. Gut. 1990;31:896–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Poitras P, Riberdy Poitras M, Boivin M, Verrier P. Evolution of visceral sensitivity in patients with irritable bowel syndrome. Dig Dis Sci. 2002;47:914–20.PubMedCrossRefGoogle Scholar
  16. 16.
    Houghton LA, Calvert EL, Jackson NA, Cooper P, Whorwell PJ. Visceral sensation and emotion: a study using hypnosis. Gut. 2002;51:701–4.PubMedCrossRefGoogle Scholar
  17. 17.
    Mulak A, Bonaz B. Irritable bowel syndrome: a model of the brain–gut interactions. Med Sci Monit. 2004;10:RA55–62.Google Scholar
  18. 18.
    Silverman DH, Munakata JA, Ennes H, Mandelkern MA, Hoh CK, Mayer EA. Regional cerebral activity in normal and pathological perception of visceral pain. Gastroenterology. 1997;112:64–72.PubMedCrossRefGoogle Scholar
  19. 19.
    Drossman DA, Ringel Y, Vogt BA, Leserman J, Lin W, Smith JK, et al. Alterations of brain activity associated with resolution of emotional distress and pain in a case of severe irritable bowel syndrome. Gastroenterology. 2003;124:754–61.PubMedCrossRefGoogle Scholar
  20. 20.
    Mertz H, Morgan V, Tanner G, Pichens D, Price R, Shyr Y, et al. Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention. Gastroenterology. 2000;118:842–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Baciu MV, Bonaz BL, Papillon E, Bost RA, Le Bas JF, Fournet J, et al. Central processing of rectal pain: a functional MR imaging study. Am J Neuroradiol. 1999;20:1920–4.PubMedGoogle Scholar
  22. 22.
    Bonaz B, Baciu M, Papillon E, Bost R, Gueddah N, Le Bas JF, et al. Central processing of rectal pain in patients with irritable bowel syndrome: an fMRI study. Am J Gastroenterol. 2002;97:654–61.PubMedCrossRefGoogle Scholar
  23. 23.
    Sternberg EM, Chrousos GP, Wilder RL, Gold PW. The stress response and the regulation of inflammatory disease. Ann Intern Med. 1992;117:854–66.PubMedGoogle Scholar
  24. 24.
    Gue M, Tekamp A, Tabis N, Junien JL, Buéno L. Cholecystokinin blockade of emotional stress- and CRF-induced colonic motor alterations in rats: role of the amygdala. Brain Res. 1994;658:232–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Sajdyk TJ, Shekhar A, Gehlert DR. Interactions between NPY and CRF in the amygdala to regulate emotionality. Neuropeptides. 2004;38:225–34.PubMedCrossRefGoogle Scholar
  26. 26.
    Swanson LW, Sawchenko PE, Rivier J, Vale WW. Organization of ovine corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: an immunohistochemical study. Neuroendocrinology. 1983;36:165–86.PubMedCrossRefGoogle Scholar
  27. 27.
    Taché Y, Monnikes H, Bonaz B, Rivier J. Role of CRF in stress-related alterations of gastric and colonic motor function. Ann NY Acad Sci. 1993;697:233–43.PubMedCrossRefGoogle Scholar
  28. 28.
    Taché Y, Martinez V, Million M, Rivier J. Corticotropin-releasing factor and the brain–gut motor response to stress. Can J Gastroenterol. 1999;13:18A–25A.PubMedGoogle Scholar
  29. 29.
    Smith GW, Aubry JM, Dellu F, Contarino A, Bilezikjian LM, Gold LH, et al. Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron. 1998;20:1093–102.PubMedCrossRefGoogle Scholar
  30. 30.
    Timpl P, Spanagel R, Sillaber I, Kresse A, Reul JM, Stalla GK, et al. Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor. Nat Genet. 1998;19:162–6.PubMedCrossRefGoogle Scholar
  31. 31.
    Cole MA, Kalman BA, Pace TW, Topczewski F, Lowrey MJ, Spencer RL. Selective blockade of the mineralocorticoid receptor impairs hypothalamic–pituitary–adrenal axis expression of habituation. J Neuroendocrinol. 2000;12:1034–42.PubMedCrossRefGoogle Scholar
  32. 32.
    Munakata J, Mayer EA, Chang L, Schmulson M, Liu M, Tougas G, et al. Autonomic and neuroendocrine responses to recto-sigmoid stimulation. Gastroenterology. 1998;114:A808.CrossRefGoogle Scholar
  33. 33.
    Heitkemper M, Jarrett M, Cain K, Shaver J, Bond E, Woods NF, et al. Increased urine catecholamines and cortisol in women with irritable bowel syndrome. Am J Gastroenterol. 1996;91:906–13.PubMedGoogle Scholar
  34. 34.
    Heim C, Newport DJ, Bonsall R, Miller AH, Nemeroff CB. Altered pituitary–adrenal axis responses to provocative challenge tests in adult survivors of childhood abuse. Am J Psychiatry. 2001;158:575–81.PubMedCrossRefGoogle Scholar
  35. 35.
    Heim C, Ehlert U, Hellhammer DH. The potential role of hypocortisolism in the pathophysiology of stress-related bodily disorders. Psychoneuroendocrinology. 2000;25:1–35.PubMedCrossRefGoogle Scholar
  36. 36.
    Stratakis CA, Chrousos GP. Neuroendocrinology and pathophysiology of the stress system. Ann N Y Acad Sci. 1995;771:1–18.PubMedCrossRefGoogle Scholar
  37. 37.
    Spiller RC, Jenkis D, Thornley JP, Hebden JM, Wright T, Skinner M, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut. 2000;47:804–11.PubMedCrossRefGoogle Scholar
  38. 38.
    Creed F. The relationship between psychosocial parameters and outcome in the irritable bowel syndrome. Am J Med. 1999;107:74–80.CrossRefGoogle Scholar
  39. 39.
    Gwee KA, Leong YL, Graham C, McKendrick MW, Collins SM, Walters SJ, et al. The role of psychological and biological factors in postinfective gut dysfunction. Gut. 1999;44:400–6.PubMedCrossRefGoogle Scholar
  40. 40.
    Aggarwal A, Cutts TF, Abell AL, Cardoso S, Familoni B, Bremer J, et al. Predominant symptoms in irritable bowel syndrome correlate with specific autonomic nervous system abnormalities. Gastroenterology. 1994;106:945–50.PubMedGoogle Scholar
  41. 41.
    Tougas G. The autonomic nervous system in functional bowel disorders. Gut. 2000;47:iv78–80.Google Scholar
  42. 42.
    Heitkemper M, Jarret M, Cain KC, Burr R, Levy RL, Feld A, et al. Autonomic nervous system in women with irritable bowel syndrome. Dig Dis Sci. 2001;46:1276–84.PubMedCrossRefGoogle Scholar
  43. 43.
    Elsenbruch S, Orr WC. Diarrhea and constipation-predominant IBS patients in postprandrial autonomic and cortisol responses. Am J Gastroenterol. 2001;96:460–6.PubMedCrossRefGoogle Scholar
  44. 44.
    Azpiroz F. Hypersensitivity in functional gastrointestinal disorders. Gut. 2002;51:i25–8.PubMedCrossRefGoogle Scholar
  45. 45.
    Gupta V, Sheffield D, Verne GN. Evidence for autonomic dysregulation in irritable bowel syndrome. Dig Dis Sci. 2002;47:1716–22.PubMedCrossRefGoogle Scholar
  46. 46.
    Chang L, Berman S, Mayer EA, Suyenobu B, Derbyshire S, Naliboff B, et al. Brain responses to visceral and somatic stimuli in patients with irritable bowel syndrome with and without fibromyalgia. Am J Gastroenterol. 2003;98:1354–61.PubMedCrossRefGoogle Scholar
  47. 47.
    Jarret ME, Burr RL, Cain KC, Hertig V, Weisman P, Heitkemper MM. Anxiety and depression are related to autonomic nervous system function in women with irritable bowel syndrome. Dig Dis Sci. 2003;48:386–94.CrossRefGoogle Scholar
  48. 48.
    Isgar B, Harman M, Kaye MD, Whorwel PJ. Symptoms of irritable bowel syndrome in ulcerative colitis in remission. Gut. 1983;24:190–2.PubMedCrossRefGoogle Scholar
  49. 49.
    Park JH, Rhee PL, Kim HS, Lee JH, Kim YH, Kim JJ, et al. Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome. Gut. 2000;47:804–11.CrossRefGoogle Scholar
  50. 50.
    Church MK, Lowman MA, Robinson C, Holgate ST, Benyon RC. Interaction of neuropeptides with human mast cells. Int Arch Allergy Appl Immunol. 1989;88:70–8.PubMedCrossRefGoogle Scholar
  51. 51.
    Arzubiaga C, Morrow J, Roberts LJ, Biaggioni I. Neuropeptide Y, a putative cotransmitter in noradrenergic neurons, induces mast cell degranulation but not prostaglandin D2 release. J Allergy Clin Immunol. 1991;87:88–93.PubMedCrossRefGoogle Scholar
  52. 52.
    Gui XY. Mast cells: a possible link between psychological stress, enteric infection, food allergy and gut hypersensitivity in the irritable bowel syndrome. J Gastroenterol Hepatol. 1998;13:980–9.PubMedCrossRefGoogle Scholar
  53. 53.
    Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES. The sympathetic nerve-an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev. 2000;52:595–638.PubMedGoogle Scholar
  54. 54.
    Gershon MD. Serotonin and its implication for the management of irritable bowel syndrome. Rev Gastroenterol Disord. 2003;3:S25–34.PubMedGoogle Scholar
  55. 55.
    Mertz H. Role of the brain and sensory pathways in gastrointestinal sensory disorders in humans. Gastroenterology. 2002;51:i29–33.Google Scholar
  56. 56.
    Mayer EA, Naliboff BD, Chang L. Basic pathophysiologic mechanisms in irritable bowel syndrome. Dig Dis. 2001;19:212–8.PubMedCrossRefGoogle Scholar
  57. 57.
    Kim DY, Camilleri M. Serotonin: a mediator of the brain–gut connection. Am J Gastroenterol. 2000;95:2698–709.PubMedGoogle Scholar
  58. 58.
    Kim HJ, Camilleri M, Carlson PJ, Cremonini F, Ferber I, Stephens D, et al. Association of distinct α2 adrenoceptor and serotonin transporter polymorphisms with constipation and somatic symptoms in functional gastrointestinal disorders. Gut. 2004;53:829–37.PubMedCrossRefGoogle Scholar
  59. 59.
    Whitehead WE, Engel BT, Schuster MM. Irritable bowel syndrome: physiological and psychological differences between diarrhea-predominant and constipation-predominant patients. Dig Dis Sci. 1980;25:404–13.PubMedCrossRefGoogle Scholar
  60. 60.
    Simrén M, Abrahamsson H, Bjornsson ES. An exaggerated sensory component of the gastrocolonic response in patients with irritable bowel syndrome. Gut. 2001;48:20–7.PubMedCrossRefGoogle Scholar
  61. 61.
    Slater BJ, Plusa SM, Smith AN, Varma JS. Rectal hypersensitivity in the irritable bowel syndrome. Int J Colorectal Dis. 1997;12:29–32.PubMedCrossRefGoogle Scholar
  62. 62.
    Harraf F, Schmulson M, Saba L, Varma JS. Subtypes of constipation predominant irritable bowel syndrome based on rectal perception. Gut. 1998;43:388–94.PubMedCrossRefGoogle Scholar
  63. 63.
    Steens J, Van Der Schaar PJ, Penning C, Brussee J, Masclee AA. Compliance, tone and sensitivity of the rectum in different subtypes of irritable bowel syndrome. Neurogastroenterol Motil. 2002;14:241–7.PubMedCrossRefGoogle Scholar
  64. 64.
    Tam FSF, Hiller K, Bunce K. Investigation of the 5-HT receptor type involved in inhibition of spontaneous activity of human colonic circular muscle. Br J Pharmacol. 1992;106:25P.CrossRefGoogle Scholar
  65. 65.
    Evangelista S. Involvement of tachykinins in intestinal inflammation. Curr Pharm Des. 2001;7:19–30.PubMedCrossRefGoogle Scholar
  66. 66.
    Holzer P, Holzer-Petsche U. Tachykinins in the gut. Part II. Roles in neural excitation, secretion and inflammation. Pharmacol Ther. 1997;73:219–63.PubMedCrossRefGoogle Scholar
  67. 67.
    Holzer P, Holzer-Petsche U. Tachykinins in the gut. Part I. Expression, release and motor function. Pharmacol Ther. 1997;73:173–217.PubMedCrossRefGoogle Scholar
  68. 68.
    Leng YX, Wei YY, Chen H, Zhou SP, Yang YL, Duan LP. Alteration of cholinergic and peptidergic neurotransmitters in rat ileum induced by acute stress following transient intestinal infection is mast cell dependent. Chin Med J. 2010;123:227–33.PubMedGoogle Scholar
  69. 69.
    Stead RH, Tomioka M, Quinonez G, Simon GT, Felten SY, Bienenstock J. Intestinal mucosal mast cells in normal and nematode-infected rat intestines are in intimate contact with peptidergic nerves. Proc Natl Acad Sci USA. 1987;84:2975–9.PubMedCrossRefGoogle Scholar
  70. 70.
    Palsson OS, Morteau O, Bozymski EM, Woosley JT, Sartor RB, Davies MJ, et al. Elevated vasoactive intestinal peptide concentrations in patients with irritable bowel syndrome. Dig Dis Sci. 2004;49:1236–43.PubMedCrossRefGoogle Scholar
  71. 71.
    Salio C, Lossi L, Ferrini F, Merighi A. Neuropeptides as synaptic transmitters. Cell Tissue Res. 2006;326:583–98.PubMedCrossRefGoogle Scholar
  72. 72.
    Farhadi A, Fields JZ, Keshavarzian A. Mucosal mast cells are pivotal elements in inflammatory bowel disease that connect the dots: stress, intestinal hyperpermeability and inflammation. World J Gastroenterol. 2007;13:3027–30.PubMedGoogle Scholar
  73. 73.
    Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004;126:693–702.PubMedCrossRefGoogle Scholar
  74. 74.
    Rodríguez-Fandiño O, Hernández-Ruiz J, Schmulson M. From cytokines to Toll-like receptors and beyond—current knowledge and future research needs in irritable bowel syndrome. J Neurogastroenterol Motil. 2010;16:363–73.PubMedCrossRefGoogle Scholar
  75. 75.
    Liebregts T, Adam B, Bredack C, Röth A, Heinzel S, Lester S, et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology. 2007;132:913–20.PubMedCrossRefGoogle Scholar
  76. 76.
    Dinan TG, Quigley EM, Ahmed SM, Scully P, O’Brien S, O’Mahony L, et al. Hypothalamic–pituitary–gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology. 2006;130:304–11.PubMedCrossRefGoogle Scholar
  77. 77.
    Wood JD. Neuropathophysiology of irritable bowel syndrome. J Clin Gastroenterol. 2002;35:S11–22.PubMedCrossRefGoogle Scholar
  78. 78.
    Stasi C, Zignego AL, Laffi G, Rosselli M. The liver–cytokine–brain circuit in interferon-based treatment of patients with chronic viral hepatitis. J Viral Hepatitis. 2011;18:525–32.CrossRefGoogle Scholar

Copyright information

© Springer 2012

Authors and Affiliations

  • Cristina Stasi
    • 1
  • Massimo Rosselli
    • 1
  • Massimo Bellini
    • 2
  • Giacomo Laffi
    • 1
  • Stefano Milani
    • 3
  1. 1.Dipartimento di Medicina InternaUniversity of FlorenceFlorenceItaly
  2. 2.Unit of Gastroenterology, Department of Internal MedicineUniversity of PisaPisaItaly
  3. 3.Department of Clinical PathophysiologyUniversity of FlorenceFlorenceItaly

Personalised recommendations